Sioux Falls, SD-(BUSINESS WIRE)-SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high potency, fully-human polyclonal antibodies, today announced that Eddie J. Sullivan, PhD, co-founder, president and CEO, will participate in a fireside chat at the RBC Capital Markets 2021 Global Healthcare Conference on Thursday, May 20, 2021 at 11:30 a.m. ET.

About SAB Biotherapeutics, Inc.

SAB Biotherapeutics, Inc. (SAB) is a clinical-stage, biopharmaceutical company advancing a new class of immunotherapies leveraging fully-human polyclonal antibodies. Utilizing some of the most complex genetic engineering and antibody science in the world, SAB has developed the only platform that can rapidly produce natural, specifically-targeted, high-potency, human polyclonal immunotherapies at commercial scale. In addition to COVID-19, the company‚Äôs pipeline also includes programs in Type 1 diabetes, organ transplant, influenza and a human immune globulin (IgG) to treat autoimmune diseases. For more information visit: or follow @SABBantibody on Twitter.


Melissa Ullerich
+1 605-695-8350

Stern Investor Relations
Courtney Turiano
+1 212-362-1200